Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
Date:12/12/2011

ad cash, cash equivalents and investments in securities totaling $81.8 million, including cash and cash equivalents of $79.5 million and restricted investments in securities of $2.3 million.

Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2011 full year financial results today, December 12, 2011, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-877-558-3407 for domestic callers or +1-706-679-1941 for international callers, and entering passcode 33791527. Those interested in listening to the conference call live via the internet may do so by visiting http://www.avanir.com.

About AVP-923AVP-923 is a combination of two well-characterized compounds: the active ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist) and low dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan. The dosage form of AVP-923 of 20 mg DM/10 mg Q capsules (twice daily) is approved by the FDA under the brand name NUEDEXTA® which is indicated for the treatment of pseudobulbar affect (PBA).

About NUEDEXTANUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is not approved for the treatment of central neuropathic pain.

NUEDEXTA Important Safety InformationNUEDEXTA can interact with other medications causing significant changes in blood lev
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
2. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
3. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
4. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
6. Avanir Pharmaceuticals to Participate in Two Investor Conferences
7. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
8. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
9. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
10. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
11. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- Global ENT (Ear, Nose, And ... 23.01 million in 2022, according to a new study ... population, increasing prevalence of ear, nose, and throat related ... target customer base are expected serve this market as ... to estimates published by the WHO, 15% of adult ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud ... predictive analytics technology, announces it is working with ... solutions for the new Lockheed Martin Healthcare Technology ... leading health information technology providers, medical technology companies ... collaboration and innovation to improve care in rapidly ...
(Date:7/30/2015)... 30, 2015  NanoSmart Pharmaceuticals, Inc., a private ... received Orphan Drug Designation from the Food and ... that uses NanoSmart,s proprietary drug delivery platform. The ... the treatment of Ewing,s sarcoma, a rare type ... Orphan Drug Designation on the basis of a ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 13, 2007 -,Cytos Biotechnology AG (SWX:CYTN) reported ... with CYT003-QbG10, an immunotherapeutic,product candidate for the ... patients suffering from mild to moderate allergic,rhinitis ... The trial,investigated in a doubleblind setting the ...
... company Pharmaxis today announced the results,from its Phase ... Pulmonary Disease (COPD), a respiratory disease,affecting over 30 ... in 79 diagnosed COPD patients at 12,centres in ... to,determine if subjects that were positive to an ...
Cached Medicine Technology:Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... “ Crack’em ... the latest and coolest technology products available to consumers. Amanda Forstrom, a technology expert ... tool helps chefs make less mess while cooking. , Cooking can be a very ...
(Date:7/31/2015)... ... , ... In the most recent testosterone lawsuit news related to ... Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” was held recently, according ... minutes of the status conference, which was held that day, according to court documents. ...
(Date:7/31/2015)... Waycross, Georgia (PRWEB) , ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels ... Park near Waycross, Georgia. Start time will be 7:30 AM. The duathlon is a 2 ... quarter mile swim in Laura Walker Lake, a 13 mile bike, and a 3 mile ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions announced today ... of Microsoft Dynamics GP for a senior living facility in Maine. Having achieved ... living communities in 16 states. This further expansion was again a factor of ...
(Date:7/31/2015)... ... July 31, 2015 , ... David ... Sinuplasty website to inform potential Nashville area sinus sufferers about the ... used to determine if someone is a good candidate for Balloon Sinuplasty. The ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3
... name, one might rhetorically ask. But Malaccan state authorities have ... after their region. And now the virus will carry some ... announced last week they discovered a new virus likely carried ... called it the Melaka Virus, using the name of the ...
... visits to hospitals and doctors, new data suggests . ... of increased birth rates, such as those during the economic ... have put the generation's birth years at 1946 to 1964. ... booming, prosperous America, admired and envied by other countries. ...
... suggests that the chances of developing breast cancer are ... cancer her daughters or sisters are over 60 ... they develop the disease. The chances of developing breast ... findings suggest survival also runs in the family. ...
... (SLE), an autoimmune disease that mainly affects women in ... shift toward improving quality of life. ,For ... future fertility. However, no studies have been conducted to ... abnormalities in male SLE patients. In addition, the study ...
... up four days of talks in Istanbul devoted to two ... how do you measure it? ,Experts attending a ... that the indices used in the past, which depended basically ... Product, were no longer valid. ,"Because we measure ...
... shifting around body fat to flatten your tummy and ... that ample fat? According to an international study ... ,The study, published online in Nature Medicine, could "revolutionise ... associated with human obesity," the Georgetown University Medical Center ...
Cached Medicine News:Health News:Mealaka Virus Will Have a New Name 2Health News:As the US Population Ages, Hospital and Doctors Visits Shoot Up 2Health News:Breast Cancer Outcomes in the Family 2Health News:Infertility is Seen in Men With SLE 2Health News:Experts in Istanbul Seek Nature and Measure of Happiness 2Health News:Stressed Mice may Hold Clue to How Fat is Stored: Study 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: